Analyst Price Target is $28.40
▲ +94.39% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for AVITA Medical in the last 3 months. The average price target is $28.40, with a high forecast of $40.00 and a low forecast of $23.00. The average price target represents a 94.39% upside from the last price of $14.61.
Current Consensus is
The current consensus among 5 investment analysts is to buy stock in AVITA Medical. This Buy consensus rating has held steady for over two years.
AVITA Medical, Inc. operates as a regenerative medicine company in the United States, Australia, Japan, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's skin. Its lead product is RECELL System, a platform technology allows for the preparation and delivery of spray-on skin cells to regenerate natural healthy epidermis, as well as to use in the treatment of acute thermal burns in patients eighteen years and older. AVITA Medical, Inc. has a research agreement with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.